Companies ALX Oncology Holdings
ALX Oncology (ALXO): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me ALX Oncology Holdings’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $4,857,183FY2023
- $6,640,830FY2024
- $2,470,844FY2025
CEO total pay was $2,470,844 in fiscal 2025, down from $6,640,830 in fiscal 2024.
FY2025: salary $724,500 · bonus $0 · stock awards $0 · option awards $1,447,488
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jason Lettmann | $724,500 | $0 | $0 | $1,447,488 | $298,856 | $0 | $0 | $2,470,844 |
| Chief Executive Officer | ||||||||
| Harish Shantharam | 464,479 | 0 | 0 | 1,084,281 | 151,913 | 0 | 0 | 1,700,673 |
| Chief Financial Officer | ||||||||
| Jaume Pons | 259,199 | 0 | 0 | 64,530 | 0 | 0 | 650,000 | 973,729 |
| Former President and Chief Scientific Officer | ||||||||
| Shelly Wong | 435,592 | 0 | 0 | 361,939 | 142,874 | 0 | 0 | 940,405 |
| Senior Vice President, Finance and Chief Accounting Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jason Lettmann | $2,470,844 | $6,640,830 | $4,857,183 | ↓ −4,169,986 |
| Harish Shantharam | 1,700,673 | — | — | — |
| Jaume Pons | 973,729 | 3,017,955 | 2,745,326 | ↓ −2,044,226 |
| Shelly Wong | 940,405 | 1,505,161 | — | ↓ −564,756 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation philosophy is market-based and designed to attract, engage, and retain executive officers who share the Company's vision. It aligns executive pay with short- and long-term performance by providing the majority of compensation in the form of variable, at-risk pay, combining competitive cash and equity awards to increase stockholder value.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Shelly Wong | RSU | 1,375 | — | $1,554 |
| Shelly Wong | RSU | 3,000 | — | 3,390 |
| Shelly Wong | Option | 5,250 | 11.47 | — |
| Shelly Wong | RSU | 6,250 | — | 7,063 |
| Shelly Wong | RSU | 9,375 | — | 10,594 |
| Shelly Wong | RSU | 9,750 | — | 11,018 |
| Shelly Wong | Option | 14,250 | 5.86 | — |
| Shelly Wong | Option | 18,959 | 15.84 | — |
| Jason Lettmann | RSU | 37,500 | — | 42,375 |
| Jason Lettmann | RSU | 42,000 | — | 47,460 |
| Shelly Wong | Option | 86,334 | 1.65 | — |
| Shelly Wong | Option | 90,000 | 0.49 | — |
| Shelly Wong | Option | 90,000 | 1.66 | — |
| Jason Lettmann | Option | 102,917 | 15.84 | — |
| Jason Lettmann | Option | 120,000 | 1.66 | — |
| Jason Lettmann | Option | 125,000 | 0.49 | — |
| Harish Shantharam | Option | 125,000 | 0.49 | — |
| Shelly Wong | Option | 140,000 | 1.7 | — |
| Harish Shantharam | Option | 198,750 | 1.7 | — |
| Jason Lettmann | Option | 368,459 | 1.65 | — |
| Jason Lettmann | Option | 525,000 | 4.92 | — |
| Jason Lettmann | Option | 597,500 | 1.7 | — |
| Harish Shantharam | Option | 600,000 | 1.65 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Alan Sandler, M.DNot independent | $1,831 | $0 | $0 | $0 | $598,958 | $600,789 |
| Barbara Klencke, M.DNot independent · Departed during FY | 35,080 | — | 51,445 | — | 465,340 | 551,865 |
| Corey Goodman, Ph.DIndependent · Board Chair · Compensation (Chair) · Partial-year service | 97,860 | 0 | 50,011 | 0 | 0 | 147,871 |
| Rekha HemrajaniIndependent · Audit (Chair) | 65,000 | 0 | 50,011 | 0 | 0 | 115,011 |
| Scott GarlandIndependent · Audit · Compensation | 63,500 | 0 | 50,011 | 0 | 0 | 113,511 |
| Chris Takimoto, M.D., Ph.D., F.A.C.PIndependent · Compensation · Partial-year service | 47,419 | 0 | 51,445 | 0 | 0 | 98,864 |
| Daniel Curran, M.DIndependent · Audit | 19,565 | 0 | 19,408 | 0 | 0 | 38,973 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $330,255 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $1,064,298 |
| Total cost of the board | $1,394,553 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names ALX Oncology as a peer
Companies that benchmark against ALXO
8 companies name ALXO as a compensation peer
- AGENUS INCAGENFY2025
- ANAPTYSBIO, INCANABFY2025
- ORAMED PHARMACEUTICALS INC.ORMPFY2024
- Passage BIO, Inc.PASGFY2025
- Perspective Therapeutics, Inc.CATXFY2025
- Repare Therapeutics Inc.RPTXFY2024
- Shattuck Labs, Inc.STTKFY2025
Each company listed discloses ALXO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ALXO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | ALX Oncology Holdings | 2025 | Jason Lettmann | $724,500 | $0 | $1,447,488 | $298,856 | $2,470,844 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 84,540,061 | 13,497,711 | 2,953,259 | 86.23% | Passed |
| 2025 | 2025-06-11 | 22,147,884 | 8,736,683 | 1,381,373 | 71.71% | Passed |
| 2024 | 2024-06-12 | 40,935,354 | 1,422,239 | 34,391 | 96.56% | Passed |
| 2023 | 2023-06-16 | 35,476,558 | 413,798 | 9,213 | 98.85% | Passed |
| 2022 | 2022-06-14 | 28,566,208 | 3,738,258 | 8,032 | 88.43% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-10 | 86.23%a |
| 2025 | 2025-06-11 | 71.71%b |
| 2024 | 2024-06-12 | 96.56%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “If you ABSTAIN from voting on Proposal No. 2, the abstention will have the same effect as a vote AGAINST the proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (17 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Jason Lettmann. DEF 14A, filed 2026-04-20. Section “Summary Compensation Table” · page 34. As printed: 2,470,844. View filing ↗
- Section 01, Harish Shantharam. DEF 14A, filed 2026-04-20. Section “Summary Compensation Table” · page 34. As printed: 1,700,673. View filing ↗
- Section 01, Jaume Pons. DEF 14A, filed 2026-04-20. Section “Summary Compensation Table” · page 34. As printed: 973,729. View filing ↗
- Section 01, Shelly Wong. DEF 14A, filed 2026-04-20. Section “Summary Compensation Table” · page 34. As printed: 940,405. View filing ↗
- Section 08, Alan Sandler, M.D. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 600,789. View filing ↗
- Section 08, Barbara Klencke, M.D. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 551,865. View filing ↗
- Section 08, Corey Goodman, Ph.D. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 147,871. View filing ↗
- Section 08, Rekha Hemrajani. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 115,011. View filing ↗
- Section 08, Scott Garland. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 113,511. View filing ↗
- Section 08, Chris Takimoto, M.D., Ph.D., F.A.C.P. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 98,864. View filing ↗
- Section 08, Daniel Curran, M.D. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 38,973. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-11. Item 5.07 · say-on-pay result. As reported: 86.23% (votes for as printed: 84,540,061). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-12. Item 5.07 · say-on-pay result. As reported: 71.71% (votes for as printed: 22,147,884). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-17. Item 5.07 · say-on-pay result. As reported: 96.56% (votes for as printed: 40,935,354). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 330,255 + equity 0 + all other 1,064,298 = 1,394,553, summed across the director compensation table rows.
- ALX Oncology Holdings (subject), Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in ALX Oncology Holdings's own proxy. As printed: 2,470,844. View filing ↗